Preventing Lethal Hospital Outbreaks of Antibiotic-Resistant Bacteria

and the Institute for Healthcare Improvement, Cambridge, MA (D.A.G.).
New England Journal of Medicine (Impact Factor: 55.87). 12/2012; 367(23):2168-2170. DOI: 10.1056/NEJMp1212370
Source: PubMed


The threat of infections due to multidrug-resistant organisms is increasing, and multidrug-resistant gram-negative rods are the most menacing such organisms. Reliable adherence to basic practices is the key to interrupting transmission in our hospitals.

10 Reads
  • Source
    • "Staphylococcus aureus (S. aureus) is a main pathogen responsible for a number of diseases from serious hospital infections and community acquired infections (Sandora and Goldmann 2012; Frisina et al. 2013). There is still no specific and selective antibacterial agents to kill Methicillin-resistant S. aureus (MRSA), which is the major cause of high death rate of patients in hospital because of its emergence, spread and rapid evolution (Gordon and Lowy 2008; Malani 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A series of bisoumarin (1-4) and dihydropyran (5-8) derivatives were successfully synthesized as new antibacterial agents. The molecular structures of three representative compounds 1, 5 and 7 were confirmed by single crystal X-ray diffraction study. Among these compounds tested toward Staphylococcus aureus (S. aureus ATCC 29213), methicillin-resistant S. aureus (MRSA XJ 75302), vancomycin-intermediate S. aureus (Mu50 ATCC 700699), and USA 300 (Los Angeles County clone, LAC), compounds 1 and 2 displayed the most potent antibacterial activity. Additionally, the HB energy in biscoumarins 1-4 was calculated by density functional theory (DFT) [B3LYP/6-31G*] method.
    Archives of Pharmacal Research 06/2015; DOI:10.1007/s12272-015-0614-7 · 2.05 Impact Factor
  • Source
    • "Antimicrobial resistance is not a new problem, but the number of resistant organisms and lethal outbreaks is unprecedented123. Infectious agents that were once supposed to be controlled by antibiotics are returning in new forms resistant to conventional therapies, clearly making efficient and stable control of microorganisms difficult45. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Peptide rational design was used here to guide the creation of two novel short β-lactamase inhibitors, here named dBLIP-1 and -2, with length of five amino acid residues. Molecular modeling associated with peptide synthesis improved bactericidal efficacy in addition to amoxicillin, ampicillin and cefotaxime. Docked structures were consistent with calorimetric analyses against bacterial β-lactamases. These two compounds were further tested in mice. Whereas commercial antibiotics alone failed to cure mice infected with Staphylococcus aureus and Escherichia coli expressing β-lactamases, infection was cleared when treated with antibiotics in combination with dBLIPs, clearly suggesting that peptides were able to neutralize bacterial resistance. Moreover, immunological assays were also performed showing that dBLIPs were unable to modify mammalian immune response in both models, reducing the risks of collateral effects. In summary, the unusual peptides here described provide leads to overcome β-lactamase-based resistance, a remarkable clinical challenge.
    Scientific Reports 08/2014; 4:6015. DOI:10.1038/srep06015 · 5.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We report the full genome sequence of hepatitis C virus (HCV) subtype 6n from Kuala Lumpur, Malaysia. Phylogenetic analysis of the isolate 10MYKJ032 suggests that Southeast Asia might be the origin for the HCV subtype 6n and highlights the possible spread of this lineage from Southeast Asia to other regions.
    Genome Announcements 01/2013; 1(1). DOI:10.1128/genomeA.00168-12
Show more